HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 8:30 AM Pacific Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20209. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
